I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| natural killer cell | 10 studies | 18% ± 3% | |
| CD16-positive, CD56-dim natural killer cell, human | 9 studies | 19% ± 4% | |
| fibroblast | 9 studies | 22% ± 9% | |
| plasma cell | 7 studies | 32% ± 9% | |
| CD16-negative, CD56-bright natural killer cell, human | 5 studies | 18% ± 2% | |
| endothelial cell | 5 studies | 20% ± 5% | |
| plasmacytoid dendritic cell | 5 studies | 21% ± 4% | |
| classical monocyte | 4 studies | 25% ± 8% | |
| plasmablast | 4 studies | 32% ± 16% | |
| epithelial cell | 4 studies | 33% ± 10% | |
| CD8-positive, alpha-beta T cell | 3 studies | 20% ± 3% | |
| mature NK T cell | 3 studies | 18% ± 3% | |
| non-classical monocyte | 3 studies | 33% ± 6% | |
| smooth muscle cell | 3 studies | 21% ± 3% | |
| pericyte | 3 studies | 21% ± 1% | |
| ciliated cell | 3 studies | 24% ± 3% | |
| abnormal cell | 3 studies | 19% ± 3% | |
| connective tissue cell | 3 studies | 18% ± 1% |
